-
公开(公告)号：US20180305320A1
公开(公告)日：2018-10-25
申请号：US15770255
申请日：2016-10-27
发明人： Blair T. Lapointe , Peter H. Fuller , Hakan Gunaydin , Kun Liu , Danielle F. Molinari , Qinglin Pu , Mark E. Scott , B. Wesley Trotter , Hongjun Zhang
IPC分类号： C07D231/56 , C07D401/04 , C07D491/052 , C07D471/04 , C07D491/107 , A61P19/02 , A61P17/06 , A61P29/00 , A61P37/02 , A61P11/06
CPC分类号： C07D231/56 , A61K2121/00 , A61P11/06 , A61P17/06 , A61P19/02 , A61P29/00 , A61P37/02 , C07D401/04 , C07D471/04 , C07D491/052 , C07D491/107
摘要： The present invention relates to compounds according to Formula I: and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
-
公开(公告)号：US09682978B2
公开(公告)日：2017-06-20
申请号：US14764616
申请日：2014-02-04
发明人： Matthew P. Christopher , Francesc Xavier Fradera Llinas , Michelle Machacek , Michelle Martinez , Michael Hale Reutershan , Manami Shizuka , Binyuan Sun , Christopher Francis Thompson , B. Wesley Trotter , Matthew E. Voss , Liping Yang
IPC分类号： C07D473/30 , C07D473/34 , C07D473/00
CPC分类号： C07D473/34 , C07D473/00 , C07D473/30
摘要： The present invention provides 2,6,7 substituted purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
-
公开(公告)号：US09637493B2
公开(公告)日：2017-05-02
申请号：US14652466
申请日：2013-12-18
发明人： Christopher Dinsmore , Francesc Xavier Fradera Llinas , Amit Ashokro Kudale , Michelle Machacek , Michael Hale Reutershan , Christopher Francis Thompson , B. Wesley Trotter , Liping Yang , Michael D. Altman , Stephane L. Bogen , Ronald J. Doll , Matthew E. Voss
IPC分类号： C07D487/04 , A61K31/519 , A61P35/00
CPC分类号： C07D487/04
摘要： The present invention provides substituted pyrrolopyrimidines of Formula I as described herein or a pharmaceutically acceptable salt or solvate thereof: The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
-
公开(公告)号：US09540377B2
公开(公告)日：2017-01-10
申请号：US14762827
申请日：2014-01-29
发明人： Carolyn Michele Cammarano , Matthew P. Christopher , Christopher Dinsmore , Ronald J. Doll , Francesc Xavier Fradera Llinas , Chaomin Li , Michelle Machacek , Michelle Martinez , Latha G. Nair , Weidong Pan , Michael Hale Reutershan , Manami Shizuka , Dietrich P. Steinhuebel , Binyuan Sun , Christopher Francis Thompson , B. Wesley Trotter , Yaolin Wang , Liping Yang , Stephane L. Bogen , Matthew E. Voss , Jagannath Panda , Anthappan Tony Kurissery
IPC分类号： A61K31/52 , C07D473/16 , C07D473/00 , C07D473/34 , C07D473/30
CPC分类号： C07D473/00 , C07D473/16 , C07D473/30 , C07D473/34
摘要： The present invention provides 2,6,7,8 Substituted Purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
摘要翻译： 本发明提供如本文所述的2,6,7,8取代的嘌呤或其药学上可接受的盐。 代表性化合物可用作HDM2蛋白的抑制剂。 还公开了包含上述化合物的药物组合物和使用其治疗癌症的潜在方法。
-
公开(公告)号：US20140179680A1
公开(公告)日：2014-06-26
申请号：US14132946
申请日：2013-12-18
发明人： Matthew P. Christopher , Francesc Xavier Fradera Llinas , Michelle Machacek , Michelle Martinez , Michael Hale Reutershan , Manami Shizuka , Binyuan Sun , Christopher Francis Thompson , B. Wesley Trotter , Matthew E. Voss , Michael D. Altman , Stephane L. Bogen , Ronald J. Doll
IPC分类号： C07D471/04 , C07D471/08 , C07D498/04
CPC分类号： C07D471/04 , C07D471/08 , C07D498/04 , C07D519/00
摘要： The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
摘要翻译： 本发明提供如本文所述的取代的咪唑并吡啶或其药学上可接受的盐或溶剂化物。 代表性化合物可用作HDM2蛋白的抑制剂。 还公开了包含上述化合物的药物组合物和使用其治疗癌症的潜在方法。
-
公开(公告)号：US10689369B2
公开(公告)日：2020-06-23
申请号：US16356172
申请日：2019-03-18
发明人： Blair T. Lapointe , Peter H. Fuller , Hakan Gunaydin , Kun Liu , Mark E. Scott , B. Wesley Trotter , Hongjun Zhang
IPC分类号： C07D403/08 , C07D401/12 , C07D401/06 , C07D491/107 , C07D491/048 , C07D487/10 , C07D487/04 , C07D405/12 , C07D403/14 , C07D403/06 , C07D231/56 , C07D403/12 , A61P19/02
摘要： The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
-
公开(公告)号：US10584121B2
公开(公告)日：2020-03-10
申请号：US15770257
申请日：2016-10-27
发明人： Hongjun Zhang , Kenneth Jay Barr , Blair T. Lapointe , Hakan Gunaydin , Kun Liu , B. Wesley Trotter
IPC分类号： C07D471/04 , A61K31/4353 , A61P37/00 , A61P11/06 , A61P19/02 , A61P29/00
摘要： The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
-
公开(公告)号：US08962611B2
公开(公告)日：2015-02-24
申请号：US14465577
申请日：2014-08-21
发明人： Matthew P. Christopher , Francesc Xavier Fradera Llinas , Michelle Machacek , Michelle Martinez , Michael Hale Reutershan , Manami Shizuka , Binyuan Sun , Christopher Francis Thompson , B. Wesley Trotter , Matthew E. Voss , Michael D. Altman , Stephane L. Bogen , Ronald J. Doll
IPC分类号： A61K31/553 , C07D471/04 , C07D519/00
CPC分类号： C07D471/04 , C07D471/08 , C07D498/04 , C07D519/00
摘要： The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
摘要翻译： 本发明提供如本文所述的取代的咪唑并吡啶或其药学上可接受的盐或溶剂化物。 代表性化合物可用作HDM2蛋白的抑制剂。 还公开了包含上述化合物的药物组合物和使用其治疗癌症的潜在方法。
-
公开(公告)号：US08846657B2
公开(公告)日：2014-09-30
申请号：US14132946
申请日：2013-12-18
发明人： Matthew P. Christopher , Francesc Xavier Fradera Llinas , Michelle Machacek , Michelle Martinez , Michael Hale Reutershan , Manami Shizuka , Binyuan Sun , Christopher Francis Thompson , B. Wesley Trotter , Matthew E. Voss , Michael D. Altman , Stephane L. Bogen , Ronald J. Doll
IPC分类号： A61K31/553 , C07D471/04 , C07D471/08 , C07D498/04
CPC分类号： C07D471/04 , C07D471/08 , C07D498/04 , C07D519/00
摘要： The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
摘要翻译： 本发明提供如本文所述的取代的咪唑并吡啶或其药学上可接受的盐或溶剂化物。 代表性化合物可用作HDM2蛋白的抑制剂。 还公开了包含上述化合物的药物组合物和使用其治疗癌症的潜在方法。
-
公开(公告)号：US10344000B2
公开(公告)日：2019-07-09
申请号：US15770255
申请日：2016-10-27
发明人： Blair T. Lapointe , Peter H. Fuller , Hakan Gunaydin , Kun Liu , Danielle F. Molinari , Qinglin Pu , Mark E. Scott , B. Wesley Trotter , Hongjun Zhang
IPC分类号： C07D231/56 , C07D401/04 , C07D491/052 , C07D491/107 , A61P19/02 , A61P17/06 , A61P29/00 , A61P37/02 , A61P11/06 , C07D471/04
摘要： The present invention relates to compounds according to Formula I: and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.063 秒)
